Tuberculosis (TB) remains a significant global health challenge, affecting millions of people each year. While progress has been made in combating the disease, one critical aspect that continues to impede effective TB treatment is the availability and costs of medicines. Ensuring access to affordable and high-quality drugs is essential for the success of tuberculosis control programs worldwide. In this article, we will explore the current landscape of TB medicines, the challenges faced in terms of availability, and the impact of costs on both patients and healthcare systems.
AVAILABILITY AND COSTS OF MEDICINES FOR THE TREATMENT OF TUBERCULOSIS
DOI:
Keywords:
Availability
medicines
tuberculosis
Abstract
References
Günther, G., Guglielmetti, L., Leu, C., Lange, C., van Leth, F., Hafizi, H., ... & Dudnyk, A. (2023). Availability and costs of medicines for the treatment of tuberculosis in Europe. Clinical microbiology and infection, 29(1), 77-84.
Larkins-Ford, J., & Aldridge, B. B. (2023). Advances in the design of combination therapies for the treatment of tuberculosis. Expert Opinion on Drug Discovery, 18(1), 83-97.
Ndong Sima, C. A. A., Smith, D., Petersen, D. C., Schurz, H., Uren, C., & Möller, M. (2023). The immunogenetics of tuberculosis (TB) susceptibility. Immunogenetics, 75(3), 215-230.
Du Bruyn, E., Stek, C., Daroowala, R., Said-Hartley, Q., Hsiao, M., Schafer, G., ... & Wilkinson, R. J. (2023). Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa. Nature Communications, 14(1), 188.
Günther, G., Guglielmetti, L., Leu, C., Lange, C., van Leth, F., Hafizi, H., ... & Dudnyk, A. (2023). Availability and costs of medicines for the treatment of tuberculosis in Europe. Clinical microbiology and infection, 29(1), 77-84.